Research programme: malaria therapeutics - Carna Biosciences
Latest Information Update: 24 Apr 2024
At a glance
- Originator Carna Biosciences; Kitasato University
- Class Antimalarials; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Malaria
Most Recent Events
- 24 Apr 2024 Early research and development is ongoing in the US and Japan (Carna Biosciences pipeline, April 2024)
- 28 Sep 2023 No recent reports of development identified for research development in Malaria in Japan
- 28 Aug 2020 No recent reports of development identified for research development in Malaria in USA